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Abstract
Background: Ovarian cancer is a metastatic disease and one of the leading causes of gynaecology malignancy-related
deaths in women. Cancer stem cells (CSCs) are key contributors of cancer metastasis and relapse. Integrins are a family
of cell surface receptors which allow interactions between cells and their surrounding microenvironment and play a
fundamental role in promoting metastasis. This study investigates the molecular mechanism which associates CSCs
and integrins in ovarian cancer metastasis.
Methods: The expression of Oct4A in high-grade serous ovarian tumors and normal ovaries was determined by
immunofluorescence analysis. The functional role of Oct4A was evaluated by generating stable knockdown (KD) of
Oct4A clones in an established ovarian cancer cell line HEY using shRNA-mediated silencing. The expression of
integrins in cell lines was evaluated by flow cytometry. Spheroid forming ability, adhesion and the activities of matrix
metalloproteinases 9/2 (MMP-9/2) was measured by in vitro functional assays and gelatin zymography. These
observations were further validated in in vivo mouse models using Balb/c nu/nu mice.
Results: We report significantly elevated expression of Oct4A in high-grade serous ovarian tumors compared to normal
ovarian tissues. The expression of Oct4A in ovarian cancer cell lines correlated with their CSC-related sphere forming
abilities. The suppression of Oct4A in HEY cells resulted in a significant diminution of integrin β1 expression and
associated α5 and α2 subunits compared to vector control cells. This was associated with a reduced adhesive ability on
collagen and fibronectin and decreased secretion of pro-MMP2 in Oct4A KD cells compared to vector control cells. In
vivo, Oct4A knock down (KD) cells produced tumors which were significantly smaller in size and weight compared to
tumors derived from vector control cells. Immunohistochemical analyses of Oct4A KD tumor xenografts demonstrated a
significant loss of cytokeratin 7 (CK7), Glut-1 as well as CD34 and CD31 compared to vector control cell-derived
xenografts.
Conclusion: The expression of Oct4A may be crucial to promote and sustain integrin-mediated extracellular matrix
(ECM) remodeling requisite for tumor metastasis in ovarian cancer patients.
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Background
Ovarian cancer is a major gynaecological malignancy
worldwide with 125,000 deaths reported each year [1].
The development of ascites and peritoneal metastases is
a major clinical issue in the prognosis and management
of ovarian cancer. A significant proportion of ovarian
cancer cells within the peritoneal ascites exist as
multicellular aggregates or spheroids which have the
capacity to invade nearby organs [2]. The pathology of
peritoneal-based metastasis includes the attachment of
shed primary ovarian tumor cells onto the mesothelial-
lined spaces of the peritoneum in the form of spheroids
resulting in multiple tumor masses necessary for secondary
growth. Current treatment strategies for advanced-stage
ovarian cancer patients results in initial remission in up to
80 % of patients [3]. However, following a short remission
period (usually 16–22 months), recurrence occurs in
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almost all patients ultimately resulting in patient mortality.
This high rate of recurrence is largely due to the ability of
tumor cells to evade the cytotoxic effects of chemotherapy
associated with intrinsic or acquired chemoresistance, a
property commonly associated with CSCs [4, 5].
The concept of CSCs supports the existence of a sub-
population of tumor cells which drive tumor growth and
progression, while also sustaining the cytotoxic pressure
imposed by therapy to promote the re-growth of ther-
apy-resistant tumors [6, 7]. In this scenario, it can be
postulated that the development of an effective ther-
apy for recurrent ovarian tumors will depend on the
identification of tumor specific CSCs, as well as the
pathways/regulators controlling their survival and
sustenance.
Oct4 (Oct3/4 or POU5F1) is a member of the POU-
domain family of transcription factors and has been
shown to play an important role in the maintenance of
self-renewal and pluripotency in embryonic stem cells
(ESCs). It is commonly expressed in unfertilized oocytes,
the inner cell mass (ICM) of a blastocyst, germ cells,
embryonic carcinoma cells and embryonic germ cells
[8]. Up regulation of Oct4 expression has been shown to
sustain an undifferentiated pluripotent stem cell state,
while a loss of Oct4 expression results in the induction
of differentiation in stem cells, producing a heteroge-
neous population of highly specialized daughter cells [8].
Additionally, Oct4 has consistently been shown to be an
integral factor necessary for the reprogramming of
somatic cells into induced pluripotent stem cells (iPSCs).
Although a cocktail of transcription factors are typically
involved in this process (eg Oct4, Sox2, Klf4 and c-Myc),
reprogramming efficiency is reduced if Oct4 is not
present, thus indicating an absolute requirement for
Oct4 in maintaining a stem cell-like state [9]. Import-
antly however, Oct4 is highly expressed in many tumor
types, suggesting that the reprogramming of somatic
cells as well as tumor development and progression may
share common cellular mechanisms [10].
The Oct4 gene encodes for three isoforms, generated
by alternative splicing of genes, known as Oct4A, Oct4B
and Oct4B1 [11, 12]. At the nucleotide level, both Oct4A
and Oct4B share exons 2–5. However, exon 1 is missing
in Oct4B and is replaced by exon 2a [11, 12]. These
differences appear to have significant biological implica-
tions on isoform function with Oct4A specifically
expressed in the nucleus of ESCs, human somatic stem
cells, tumor stem cells and in some adult stem cells
[11, 12]. Oct4B on the other hand, is localised to the
cytoplasm and expressed at low levels in human som-
atic stem cells, tumor cells, adult tissues as well as
pluripotent stem cells. For investigations in stem cell
biology, it is therefore crucial that the Oct4A isoform
is specifically targeted.
The interaction between CSCs and the neighbouring
microenvironment forms a ‘niche’ which is critical for
sustaining the stemness of cancer cells [12]. Integrins
are heterodimeric transmembrane receptors composed
of a combination of different α and β subunits. They are
essential in sensing the microenvironment and triggering
cellular responses by bridging physical connections
between the interior and exterior environments of cells
[13]. This allows the flow of bi-directional signals that
control basic cellular functions such as adhesion, migra-
tion, proliferation, and survival as well as differentiation
[13]. In the context of CSCs, integrin receptors have
been shown to promote a more malignant phenotype for
tumor promotion and drug resistance [14, 15]. These
receptors are highly expressed in stem cell niches and
contribute to diverse CSC functions [14–16]. In this
study using cancer cell lines, we demonstrate a direct
link between the expression of α2, α5 and β1 integrin
subunits with Oct4A expression in ovarian cancer and
discuss the implications of these findings in relation to
CSCs and progression of ovarian cancer in patients.
Methods
Patient samples
Tissue collection
Primary high grade serous epithelial ovarian tumors and
normal ovarian tissues were obtained from patients
requiring surgical resection at The Royal Women’s
Hospital, Melbourne, Australia. The histopathological
diagnosis, tumor grades and stages were determined by
anatomical pathologists at the Royal Women’s Hospital
as part of clinical diagnosis. Patients who were treated
with chemotherapy prior to surgery were excluded from
specimen collection. Tissues were paraffin embedded or
snap frozen at the time of collection and stored at −80 °C
until processed.
Cell lines
Four established human epithelial ovarian cancer cell
lines SKOV3, OVCAR5, OVCA433, and HEY were used
in this study. The growth conditions of these cell lines
have been described previously [17]. The human ovarian
surface epithelial cell line (IOSE398) transfected with the
SV-40 antigen was obtained from Dr Nelly Auersperg,
University of British Columbia, Canada [18]. The devel-
opment of the vector control, Oct4A KD1 and Oct4A
KD2 cell lines and their growth conditions have been de-
scribed previously [19]. Cells were routinely checked for
mycoplasma infection.
Antibodies
Mouse monoclonal anti-human Oct4A and Sox2 were ob-
tained from R&D Systems (Minneapolis, Minnesota, USA)
and Cell Signalling Technology (Danvers, Massachusetts,
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USA) respectively. Rabbit polyclonal anti-human GAPDH
was obtained from IMGENIX (CA, USA). Mouse anti-
human integrin α2 (CD49b), anti-human α5 integrin
(CD49e) and anti-human β1 (CD29) were obtained from
Millipore (Billerica, Massachusetts, USA). Goat F(ab')2
anti-mouse IgG was purchased from Southern Biotech
(Birmingham, AL, USA). Rabbit polyclonal anti-human
cytokeratin 7 (CK-7), anti-human Glut-1, anti-human
CD34 and anti-human CD31 were obtained from Ventana
(Tucson, USA). The DAPI nucleic acid stain and Alexa
Fluor® 488 goat anti-mouse IgG were obtained from Life
Technologies (Carlsbad, CA, USA). Ventana antibodies
used for the immunohistochemical staining of tumor
xenografts were obtained from Roche (Basel, Switzerland)
as described previously [19–21].
Immunofluorescence analysis
For primary tissue analysis, paraffin embedded tissue
samples were sectioned at 5 μm and deparaffinised by
xylene and graded ethanol wash. Slides were blocked for
10 min in CAS-Block™ Histochemical Reagent (Invitrogen
Corporation). For non-adherent sphere populations, 100–
200 μL of sphere containing media was added per cham-
ber well containing 200 μL appropriate fresh growth
media and cultured on 8 well μ-Slides (ibidi, Martinsried,
Germany) for 24 h to allow for adhesion to plastic before
being fixed with 4 % paraformaldehyde. Monolayer cell
lines were seeded at 5 × 103 cells per well onto the 8-well
Nunc™ Lab-Tek™ Chamber Slide™ System (Thermo Scien-
tific) and cultured as monolayer in complete RPMI-1640
growth media before being fixed with 4 % paraformalde-
hyde. Samples were probed overnight at 4 °C with either
Oct4A (1:200), integrin β1 (1:200) or integrin α5 (1:200)
primary antibodies, detected with Alexa Fluor® 488 Goat-
Anti-Mouse antibody (1:200) and counterstained with 4’,6-
diamidino-2-phenylindole (DAPI) (1:10,000). Fluorescence
imaging was visualized and captured using an Olympus
CellR fluorescence microscope and associated software
(Olympus Corporation, Tokyo, Japan). Semi-quantitative
analysis to assess fluorescence intensity of the antibody of
interest was performed using the inbuilt CellR software.
Results are expressed as a fold change of the protein of
interest compared to DAPI for each analysis.
RNA extraction and real-time PCR
Quantitative real-time PCR was performed as described
previously [19]. Relative quantification of gene expression
was normalized to 18S and calibrated to the appropriate
control sample using the SYBR Green-based comparative
CT method (2-ΔΔCt). The primer set of Oct4A and β1
integrin are described in Table 1. The probe for 18S has
been described previously [22].
Western blotting
Cell lysates were extracted using the NU-PER nuclear
and cytoplasmic extraction kit (Thermo Scientific,
Waltham, MA, USA) as per manufacturer’s instructions.
SDS-PAGE and Western blot was performed on the cell
lysates as described previously [19].
Sphere forming assay
The sphere forming ability of cells and subsequent
sphere adhesion ability was determined as described pre-
viously [19]. Cellular aggregates with a diameter greater
than 200 μm were classified as spheres.
Flow cytometric analysis
Flow cytometry was used to assess the expression of cell
surface makers as described previously [23]. Briefly, cells
were grown as monolayer cultures, harvested and 106
cells incubated with primary antibody (1:100) for 30
mins at 4 °C. Cells were washed with 1X PBS, stained
with secondary Goat F(ab’)2 anti-mouse IgG antibody
conjugated with phycoerythin for 30 mins at 4 °C and
resuspended in 200 μL 1XPBS prior to flow cytometry
analysis. All data was analysed using Cell Quest software
(Becton-Dickinson, Bedford, MA, USA) and expressed
as background IgG staining subtracted from the IgG
staining of the antibody of interest.
Adhesion assay
Cell adhesion assays were used to assess the ability of cells
to adhere to extracellular matrix proteins. Briefly, 5 × 104
cells were seeded in complete growth media on culture
plates pre-coated with 10 μg/mL collagen, Type 1 (Sigma-
Aldrich) or 10 μg/mL fibronectin (Sigma-Aldrich) with
sterile 1X PBS used as a diluent. Cells were incubated for
90 mins at 37 °C in a humidified atmosphere in the pres-
ence of 5 % CO2. The growth media was removed and
cells were washed vigorously with 1X PBS using an orbital
rocker on full speed twice for 5 mins to remove non-
adhering cells. Cells were fixed with 4 % paraformaldehyde
before being stained for 10 mins with 5 % Crystal Vio-
let (Sigma-Aldrich) diluted in 0.2 % ethanol. Follow-
ing crystal violet staining, cells were gently rinsed
with 1X PBS and plates allowed to dry at room
temperature before performing a dry reading at
Table 1 Primer sequences of oligos used in quantitative Real-Time
PCR
Oligo name Forward (F) 5’-3’
Reverse (R) 5’-3’
Primer sequence
Oct4A F CTC CTG GAG GGC CAG GAAT C
R CCA CAT CGG CCTG TGT ATA T
Integrin β1 F ATC CCA GAG GCT CCA AAG AT
R CTA AAT GGG CTG GTG CAG TT
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OD550nm with the SpectraMax190 Absorbance Micro-
plate Reader and SoftMax® Pro Computer Software
(Molecular Devices). Adhesion was calculated by sub-
tracting the OD550nm reading of the negative control
from the OD550nm reading of coated wells.
Gelatin zymography
This was performed as described previously [24]. Briefly,
complete growth medium from cells grown as sub-
confluent monolayer cultures was discarded and replaced
by serum free medium in a humidified atmosphere at 37 °C
in the presence of 5 % CO2. After 48 h, the serum free
medium was collected and concentrated using 10 kDa
Amicon Ultra-4 spin columns (Merck-Millipore, Billerica,
MA, USA). Samples were resolved on 10 % (v/v) Tris–HCl
acrylamide gels containing 0.1 % (w/v) gelatin, washed and
stained with 0.2 % Coomassie blue. The gel was de-stained
and areas void of blue stain indicative of areas of enzyme
activity. Semi-quantitative densitometric analysis was per-
formed on all gels to determine the extent of enzymatic di-
gestion using Image Quant software (GE Healthcare) and
expressed as the intensity of Pro-MMP9 or Pro-MMP2
bands of interest.
Animal studies
Animal experiments were performed on Balb/c nude
mice as described previously [19–21, 25, 26].
Immunohistochemistry of mouse tumors
Immunohistochemistry analysis of mouse tumors was
performed as described previously [19–21, 25, 26].
Statistical analysis
All results are presented as the mean ± standard error of
the mean (SEM) of three independent experiments
unless otherwise indicated. Statistical significance was
measured compared to the vector control using one
way-ANOVA and Dunnett’s Multiple Comparison test
unless otherwise indicated. For primary tissue analysis,
Student’s t-test was used to compare normal and high
grade tissue samples. A probability level of <0.05 was
adopted throughout to determine statistical significance.
Results
Expression of Oct4A in serous ovarian tumors
We have previously shown enhanced expression of
Oct4A in different histological grades of serous ovarian
tumors compared to normal ovarian epithelium by immu-
nohistochemistry [19]. In this study, we confirmed our
previous results on normal and high-grade serous tumors
using immunofluorescence and Western blot techniques.
We demonstrate signifcant nuclear expression of Oct4A
in high-grade serous tumors compared to normal ovarian
tissues by immunofluorescence (Fig. 1a-d). This was
confirmed by Western blot analysis performed on nuclear
extracts of normal and tumor samples, where a higher
Oct4A expression was observed in serous tumor samples
compared to normal ovarian tissues (Fig. 1e-f). However
due to small sample size, this result was not statistically
significant (P = 0.226). These results confirm the nuclear
localisation and expression of the stem cell specific Oct4A
isoform in serous ovarian tumors and confirms that
Oct4A expression increases in high-grade serous tumors
compared to normal ovaries.
Association between endogenous Oct4A expression and
sphere forming abilities of ovarian cancer cell lines
The positive identification of Oct4A in primary serous
ovarian tumors suggests a possible biological role of
Oct4A in the disease. Using quantitative real-time PCR
analysis, we have previously shown mRNA expression of
Oct4A in four ovarian cancer cell lines OVCAR5,
SKOV3, OVCA 433 and HEY [19]. All cell lines with the
exception of OVCA433 expressed significantly elevated
levels of Oct4A mRNA when compared to the immor-
talized normal ovarian surface epithelium cell line
ISOE398 [19]. The HEY cell line was found to express
the greatest endogenous level of Oct4A mRNA with a 6-
fold increase in Oct4A expression, compared to the nor-
mal ISOE398 cell line. OVCAR5 and SKOV3 cells both
exhibited a 4-fold increase in Oct4A mRNA expression
compared to the normal ovarian cell line ISOE398 [19].
As the formation of multi-cellular aggregates within
the ascites of ovarian cancer patients has been described
as an important feature for the long term preservation
of CSCs [27, 28], and also indicative of advanced-stage
aggressive disease [28, 29], the expression of Oct4A was
correlated to the ability of each cell line to form non-
adherent spheres in ultra-low attachment plate cultures
over 18 days (Fig. 2a). Within 24 h of culture, all four
ovarian cancer cell lines demonstrated the ability to
form loose multicellular aggregates (Fig. 2a). However,
with prolonged time in culture, loose aggregates eventu-
ally formed tightly compact, rounded spheres which in-
creased in size over time (Fig. 2a). Detailed morphological
analysis of spheres using light microscopy demonstrated
HEY cells to be the first to produce dense compact
spheres 7 days post plating. Conversely, OVCAR5, SKOV3
and OVCA433 cells all required a minimum of 14 days in
culture to form compact spheres (Fig. 2a). By day 18 in
culture, noticeable differences in sphere sizes were noted
between the cell lines, with OVCA433 cells producing the
smallest spheres in diameter (~50–100 μM) followed by
SKOV3 (~75–150 μM), OVCAR5 (~100–250 μM) and
HEY (200–500 μM).
The viability of 18 day spheres produced by the ovarian
cancer cell lines was assessed by their capacity to adhere
to plastic. Under light microscopy, the spheres produced
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by the ovarian cancer cell lines adhered to plastic
within 24 h (Fig. 2b). Further microscopic evaluation
demonstrated these adhered spheres underwent cellu-
lar dispersion away from the sphere core. This effect
was predominately seen in spheres produced by
Oct4A abundant HEY cells and to a lesser extent in
spheres derived from other ovarian cancer cell lines.
The expression of Oct4A however, was not related to
the degree of adhesion of the spheres, with Oct4A
low expressing OVCA433 producing several smaller
adhered colonies compared to those produced by high
Oct4A expressing HEY cell line (Fig. 2b). OVCAR5
and SKOV3 cell lines which had moderate endogen-
ous level of Oct4A produced several colonies which
were both smaller and fewer when compared to those
produced by HEY cells.
shRNA mediated knockdown of Oct4A in HEY ovarian
cancer cell line
In order to determine the potential biological functions
of Oct4A in serous ovarian tumors, stable Oct4A knock-
down clones were generated in the metastatic ovarian
cancer cell line HEY using shRNA-mediated methods as
described previously [19]. Two clones Oct4A KD1 and
Oct4A KD2 which showed a knockdown efficiency of
~80 % at the mRNA level (Fig. 3a) and a significant
50–60 % decrease at the protein level compared to
vector control cells (Fig. 3b-c) was used in this study.
a d
b e
f
c
Fig. 1 Expression and localization of Oct4A in normal ovarian epithelium tissues and high-grade serous ovarian tumors. a-d The expression
and localisation of Oct4A in normal ovarian epithelium and primary grade 3 serous tumor samples was evaluated using immunofluorescence
staining. Tumor tissues were immunostained using a mouse monoclonal Oct4A-specific antibody and visualized using the secondary Alexa
488 fluorescent labelled antibody (green). Nuclear staining was visualized using DAPI staining (blue). Images show Oct4A expression in the
nuclei of tumor cells. Images are representative of n = 3 normal ovarian epithelium and n = 3 primary grade 3 serous ovarian tumor samples.
Magnification is set at a 100x, b 200x and c 400x. Scale bar represents 100 μM. d Mean fluorescence intensity of Oct4A staining was quantified
on images taken at 200x magnification using Cell-R software. Data is presented as the mean ± SEM of Oct4A expression standardized to DAPI of three
independent samples. Significance is indicated by *P< 0.05 as determined by student’s t-test. e Nuclear cell lysates extracted from human normal ovarian
epithelium tissues and primary high-grade serous ovarian tumors were evaluated for Oct4A protein expression using Western blot analysis. The Oct4A
protein band of interest is indicated by an arrow at ~50 kDa. Total protein load was determined by stripping and re-probing the membrane with GAPDH.
f Densitometry analysis of Oct4A Western blots. Data is expressed as a ratio of Oct4A protein expression standardized to GAPDH and presented as
the mean ± SEM
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Diminution of Oct4A suppresses integrin β1 and α5
subunits expression in HEY spheres
We have previously shown that suppression of Oct4A in
HEY cells resulted in an inability of HEY cells to form
tightly compact spheres as well as subsequent adherence
on plastic [19]. We and others have previously shown
that integrins can mediate several aspects of ovarian
tumor cell behavior including tumor cell matrix
adhesion, sphere formation and peritoneal metastasis
[15, 30, 31]. In this study we investigated the profile of
the integrin β1 subunit in adhered Oct4A KD spheres
after 18 days in culture by immunofluorescence. As
expected, integrin β1 expression was localized in the
membrane of cells making up the spheres as well as in
cells migrating away from the sphere cores (Fig. 4a).
When assessed semi quantitatively, the expression of the
integrin β1 subunit was significantly reduced ~50 % in
the cells migrating away from the sphere core of adhered
Oct4A KD spheres compared to vector control spheres
(Fig. 4b). The results of quantitative real-time PCR
analysis correlated with immunofluorescence analysis,
with Oct4A KD1 non-adherent spheres demonstrating a
a
b
Fig. 2 Sphere forming abilities and adhesion profiles of spheroids produced from epithelial ovarian cancer cell lines. a 1 x 105 OVCAR5, SKOV3,
OVCA433 and HEY cells were plated on ultra-low attachment plates in the presence of complete growth medium and sphere formation was monitored
over 18 days. Images are representative of 3 independent experiments and taken from a section of a 6 well plate well using an inverted phase contrast
microscope at 100x magnification. Scale bar represents 100 μM. b 18 day spheroids derived from OVCAR5, SKOV3, OVCA433 and HEY cells
were collected, plated and cultured on plastic for a further 24 h. Images of adhered spheres were taken using an inverted phase contrast
microscope at 100x magnification. Scale bar represents 100 μM. Adhered spheroids were also assessed by crystal violet staining to determine colony
formation. Images are that of an entire well of a 6 well plate and representative of 3 experiments prepared in triplicate
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significant 50 % decrease in integrin β1 subunit mRNA
expression compared to non-adherent vector control
spheres (Fig. 4c). Although not significant, Oct4A KD2
non-adherent spheres demonstrated a 30 % decrease in
integrin β1 mRNA expression compared to non-
adherent vector control spheres.
Given that the integrin β1subunit is known to couple
with several α integrin sub-units, the expression of the
integrin α5 subunit was also investigated in adhered
Oct4A KD spheres using immunofluorescence analysis
(Fig. 4d and e). Similar, to that of integrin β1, the integ-
rin α5 subunit was significantly down regulated by 50 %
in both Oct4A KD1 and Oct4A KD2 spheres compared
to vector control spheres. The localization of integrin α5
remained confined to the cell membranes making up the
spheres and migrating cells.
Attenuation of Oct4A suppresses integrin β1, α2 and α5
subunit expression in HEY monolayer cells and affects the
adhesive ability of HEY cells to ECM proteins collagen
and fibronectin
The cell surface expression of integrin β1 and associated
α-subunits was further assessed in monolayer cultures of
Oct4A KD cells by flow cytometry (Fig. 5a and b). The
results revealed the expression of β1, α2, and α5 integrin
subunits to be significantly down regulated in HEY cells
following shRNA-mediated knockdown of Oct4A com-
pared to vector control cells. Endogenous expression of
integrin β1 was seen to decrease ~65–70 %, while integ-
rin α2 expression was suppressed 30–40 %. α5 was seen
to decrease by 30–40 % (Fig. 5a-b). Loss of β1, α2, α5
integrin subunits also correlated with a significant
decrease in cellular adhesion to collagen and fibronectin
by Oct4A KD cells compared to vector controls
(Fig. 5c).
Diminution of Oct4A reduces secreted levels of pro-MMP2
but not MMP9 in monolayer cultures of HEY cells
Successful metastasis of disseminated ovarian cancer
cells is not only driven by tumor cell adhesion in the
peritoneal cavity, but also requires active degradation of
extracellular matrix (ECM) to invade the mesothelial
lining of the peritoneum [32, 33]. MMP secretion and
activity by ovarian tumor cells have previously been
implicated in the remodeling of ECM during the process
of metastasis [34]. As a measure of invasive ability, the
secretion of pro-MMP2 and pro-MMP-9 by Oct4A KD
cells was investigated using gelatin zymography (Fig. 6).
a c
b
Fig. 3 Stable shRNA knockdown of Oct4A in HEY ovarian cancer cell line. a The efficiency of Oct4A knockdown was evaluated by quantitative real-
time PCR analysis. Relative quantification of Oct4A expression was standarized to 18S housekeeping gene and normalised to vector control cells. Data
is from three independent samples assessed in triplicate. b The expression and localization of Oct4A in HEY cells following stable shRNA knockdown of
Oct4A was also evaluated using immunofluorescence staining. Cells were immunostained using mouse monoclonal Oct4A-specific antibody and
visualized using the secondary Alexa 488 fluorescent labelled antibody (green). Nuclear staining was visualized using DAPI staining (blue). Images are
representative of three independent experiments. Magnification is set at 200x. Scale bar is set at 50 μM. c Mean fluorescence intensity of Oct4A staining
is presented as the mean ± SEM of Oct4A expression standardized to DAPI of three independent experiments. Data is from three independent
samples assessed in triplicate. Significance is indicated by **P < 0.01 and ***P < 0.001 as determined by One-Way ANOVA using Dunnett’s
Multiple Comparison post-test against the HEY vector control
Samardzija et al. BMC Cancer  (2016) 16:432 Page 7 of 16
Pro-MMP2 levels were significantly reduced by ~70 % in
the conditioned medium obtained from Oct4A KD cells
compared to vector control cells (Fig. 6a-b). However,
no significant change in pro-MMP9 secretion was ob-
served when compared to vector control cells (Fig. 6c).
Activated secretion of MMP2 and MMP9 could not be
detected.
Attenuation of Oct4A expression decreases in vivo
tumorigenicity of HEY cells in the BALB/c nude mouse
model
To investigate the biological relevance of Oct4A in
vivo, intraperitoneal (ip) xenografts were developed
with Oct4A KD cells and vector control cells in Balb/
c nude mice. Four weeks post inoculation, 90 % of
mice (10/11) injected with vector control cells dis-
played characteristics of metastatic advanced-stage
disease including abdominal distention and weight
loss (Fig. 7). In comparison, mice injected with Oct4A
KD cells appeared to be healthy with no apparent
visible tumors within 4 weeks post inoculation. How-
ever, after surgical dissection, there were tumors
which were fewer in number and significantly smaller
in size and weight compared to mice injected with
vector control cells (Fig. 7a-c). On average, mice
injected with vector control cells produced tumors
which were 7.4 mm ± 1.4 in diameter. In comparison,
tumors derived from Oct4A KD cells were approxi-
mately 50 % smaller in size. Tumors derived from
Oct4A KD1 cells were 3.1 mm ± 0.7 in diameter,
while those derived from Oct4A KD2 cells produced
tumors 3.9 mm ± 0.40 in diameter (Fig. 7b). A similar
trend was observed when considering total tumor
weight, with mice injected with vector control cells
developing an average l tumor weight of 1.60 g ± 0.34,
equivalent to 12.58 % ± 1.88 of total mouse body
weight (Fig. 7c). In contrast, tumors derived from
mice inoculated with Oct4A KD1 cells exhibited an
average tumor weight of 0.15 g ± 0.05, equivalent to a
tumor burden of 1.33 % ± 0.45 of total mouse body
a d
b c e
Fig. 4 β1 and α5 integrin subunit expression and localisation in HEY Oct4A knockdown spheres. Expression and localisation of β1 and α5 integrin
subunits in 18 day Oct4A KD spheres was evaluated using immunofluorescence staining. Adhered spheres were immunostained using mouse
monoclonal antibodies for integrin a β1 or integrin d α5 and visualised using the secondary Alexa 488 fluorescent labelled antibody (green).
Nuclear staining was visualised using DAPI staining (blue). Magnification is set at 100x for top and middle image panels and 200x for images in
the bottom panel. Scale bar is set at 50 μM. Mean fluorescence intensity of b β1 and e α5 staining is presented as the mean ± SEM of respective
integrin expression standardised to DAPI from 3 independent experiments. c Quantitative real-time PCR analysis was used to determine the
expression of integrin β1 subunit in non-adherent 18 day Oct4A KD spheres. Relative quantification of mRNA expression was standardised to 18S
housekeeping gene and normalised to the vector control. Data is expressed as the mean fold change ± SEM from three independent samples
assessed in triplicate. Significance is indicated by *P < 0.05 and **P < 0.01 as determined by One-Way ANOVA using Dunnett’s Multiple Comparisons
post test against the vector control
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weight, while Oct4A KD2 mice exhibited a tumor weight
of 0.25 g ± 0.04, equivalent to 2.33 % ± 0.41 of total body
weight (Fig. 7c). This indicates that suppression of Oct4A
in HEY cells reduces the formation of tumors in vivo by
80–90 % compared to vector control cells within the first
few weeks of tumor development.
Knockdown of Oct4A reduces the expression of CK7,
Glut-1, CD31 and CD34 in xenografts derived from
Oct4A KD cells compared to vector control cells
Immunohistochemical analysis of mouse tumors re-
vealed that the expression of CK7, an important marker
used for the diagnosis of ovarian cancer [34], was
a
b
c
Fig. 5 Expression of integrin α2, α5 and β1 subunits in HEY Oct4A knockdown monolayer cells as determined by flow cytometry. a Flow
cytometric analysis was used to examine integrin α2, α5 and β1 subunit expression in monolayer Oct4A KD cells. Cells were cultured,
collected and incubated with respective primary antibodies or negative IgG control before being detected using a secondary goat
anti-mouse IgG conjugated with phycoerythrin. Vector control cells are represented by solid black peaks and broken peaks are indicative
of Oct4A KD cells as indicated. The filled histogram denotes the negative control IgG. b Semi-quantitative analysis of flow cytometry
results. Results are expressed as the difference between the arbitrary fluorescence expression of the integrin of interest and the negative
control IgG and presented as the mean ± SEM of four independent experiments (except integrin α5, n = 3). Significance is indicated by
*P < 0.05, **P < 0.01 and ***P < 0.001 as determined by One-Way ANOVA with Dunnett’s Multiple Comparison post-test compared to vector
control. c The adhesive ability of Oct4A KD cells on collagen and fibronectin was determined by 24 h adhesion assay. The number of
adhered cells was estimated by measuring the optical absorbance at OD550nm with the SpectraMax190 Absorbance Microplate Reader.
Data is expressed at the mean ± SEM of three independent experiments performed in triplicate. Significance between Oct4A KD cells
and vector control cells per ECM group is indicated by ***P < 0.001 as determined by Two-Way ANOVA and Bonferroni post-test
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significantly reduced by 1.1–1.6 fold in tumors derived
from Oct4A KD cells (Fig. 8a-b), compared to tumors
derived from vector control cells. Significant reduc-
tion in CK7 in Oct4A KD derived tumors correlated
with ~30 % reduction in the expression of glucose
transporter Glut-1 in tumor xenografts (Fig. 8a-b).
The staining of CK7 and Glut-1 was predominately
localized to the cytoskeletal membranes of tumor
cells. However, reduced expression of Glut-1 was only
significant in tumor xenografts derived from Oct4A
KD2 cells.
To assess whether the reduced tumor size/weight in
Oct4A KD cell-derived tumors may result from reduced
tumor vascularity, we assessed the expression of human
specific angiogenesis markers CD31 and CD34 on
mouse xenografts. Compared to tumors derived from
vector control cells, the staining intensity of both CD31
and CD34 were significantly reduced in tumors derived
from both Oct4A KD cell lines (Fig. 9). Specifically,
CD31 expression was reduced 4-fold and 2-fold in tu-
mors derived from Oct4A KD1 and Oct4A KD2 cells re-
spectively. Similarly, CD34 expression was reduced by
16-fold in tumor xenografts derived from Oct4A KD1
cells compared to only 2.5-fold decrease in Oct4A KD2
cells derived xenografts. These observations were con-
sistent with the reduced tumor size, weight and growth
potential observed in tumor xenografts derived from
Oct4A KD compared to vector control cells.
Discussion
It is well recognized that the interaction between tumor
cells and the ECM in the rapidly evolving tumor micro-
environment is essential for the generation of regulatory
signals that ultimately determine the fate of tumor cells
and influence the evolution of a malignant phenotype
[35]. The integrin family of cell surface receptors is an
important component of the ECM which sense micro
environmental changes and trigger a range of cellular
a
b c
Fig. 6 MMP9 and MMP2 secretion by HEY Oct4A KD monolayer cells. a Gelatin zymography analysis of MMP9 and MMP2 secretion by HEY Oct4A
KD cells was performed on a 10 % polyacrlamide gel containing 1 % gelatine. Pro-MMP9 (~92 kDa) and Pro-MMP2 (~72 kDa) gelatinolytic activity
is indicated by clear banding. b-c Densitometric analysis of gelatin zymography was performed to determine secreted Pro-MMP9 and Pro-MMP2
activity. Enzymatic activity is expressed as the intensity of the Pro-MMP9 and Pro-MMP2 bands of interest and presented as the mean ± SEM from
three independent experiments. Significance is indicated by *P < 0.05 as determined by One-Way ANOVA using Dunnett’s Multiple Comparison
post-test against HEY vector control cells
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responses by forming a physical link between the inside
and outside of tumor cells. Moreover, they allow for the
bidirectional regulation of signals necessary to promote
tumor progression [14]. However, it is not yet clear if
the effects that integrins have in modulating tumor cell
behavior are also related to their associated role with
CSCs in the tumor microenvironment. In this study we
demonstrate a direct association between CSC specific
Oct4A transcription factor expression and the β1 family
of integrins primarily the α2 and α5 subunits.
In a previous study, we demonstrated significantly
enhanced expression of the stem cell specific Oct4A
isoform which increased according to histological grades
of serous ovarian tumors compared to normal ovarian
epithelium by immunohistochemical methods [19]. In
this study we further validate these results in high-grade
serous ovarian tumor samples using immunofluores-
cence and Western blot techniques. We demonstrate
that the expression of Oct4A is enhanced in high-grade
serous samples compared to normal ovaries and local-
ized to the nucleus of tumor cells. These results support
the hypothesis that Oct4A has a specific role in ovarian
cancer progression.
We have previously demonstrated that suppression of
Oct4A is capable of inhibiting sphere forming abilities in
the HEY ovarian cancer cell line [19]. To expand on this
observation, the expression of Oct4A in a range of ovar-
ian cancer cell lines was seen to be directly correlated to
the anchorage independent sphere forming abilities of
each cell line. Sphere formation has been identified as a
property of CSCs and the phenomenon has been
reported in leukemia and in solid tumors of breast,
colon and brain [27]. However, the molecular mechanisms
of how sphere-forming cells retain their stem-like
characteristics remain unknown. Recent studies, have
demonstrated that mouse ESCs are capable of maintaining
a b
c
Fig. 7 Tumor development by HEY Oct4A knockdown cells in BALB/c nude mice. a HEY vector control, Oct4A KD1 or Oct4A KD2 cells were
inoculated by ip injection into 6–8 week old female BALB/c nude mice (n = 8 group). Mice were monitored daily for tumor development before
being culled, dissected and photographed at 4 weeks post injection. Arrows indicate the location of small tumor nodules. b Average tumor size
debulked from mice inoculated with vector control and Oct4A KD cells. Each tumor excised was individually measured before tumour size
averaged for each mouse. Data is expressed as the mean ± SEM of tumour size (cm) for each group (n = 8 mice/group). c Average weight of
tumors derived from vector control and Oct4A KD1 and Oct4A KD2 mice. Data is presented as the mean ± SEM of tumor weight (grams)
obtained from each mouse (n = 8 mice/group)
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long-term stemness within a 3D scaffold by manipulating
integrin signaling [36, 37]. These studies reported greatly
increased expression of known stem cell markers Oct4
and Nanog was associated with simultaneous activation of
Akt1 and Smad1/5/8 by α5β1, αvβ5, α6β1 and α9β1
integrins within the 3D scaffold. This maintained the self-
renewal capacity of ESCs in the absence of leukemia
inhibitory factor (LIF) signaling [37]. These studies suggest
that a ‘stem cell niche-specific integrin signaling mechan-
ism’ within a 3D microenvironment can sustain the
survival of ESCs without signals received from growth
factors like LIF which are absolutely essential for the
survival of ESCs.
Many of the same integrins which support ESC fate
are also markers of CSCs in different cancers [15]. These
include α6 integrin enriching for CSCs in breast [38],
prostate [39], squamous cell carcinoma [40] and colorectal
cancer [41]. Integrin β3 is critical for stemness in breast
[42, 43], pancreas [44] and lung cancer [44], while β1
integrin is necessary for the stemness characteristics in
glioblastomas [45]. These studies are in agreement with
our findings which demonstrate that integrins β1, α2 and
α5 were down regulated by the knockdown of stem cell-
specific Oct4A expression in HEY cell line. These
observations were made in cells maintained as mono-
layer as well as sphere cultures and were consistent
with the loss of adhesion of these cells on collagen
and fibronectin. However, it should be noted, that
integrins can also influence CSC niches independent
of their capacity to interact with ECM [15].
We have previously shown that enhanced expression
of α2β1 integrin in ovarian cancer spheres facilitates
sphere disaggregation, pro-MMP-2/9 expression and
MMP-2/9 activation [31]. In the current study, this is
consistent with a decrease in α2 and β1 integrin expres-
sions in Oct4A knockdown HEY cells along with
reduced pro-MMP-2 secretion. This data correlates to
the loss of sphere disaggregating and migratory ability
previously shown in Oct4 KD cells [19]. These observa-
tions in our Oct4A knockdown model are consistent
with observations in pancreatic cell line models, where
loss of Oct4 also resulted in reduced MMP2 expression
and subsequent reduced tumor cell invasive ability [46].
Interestingly, MMP2 is known to actively degrade fibro-
nectin and collagen I [32, 33, 47], thus potentially linking
these results to the decreased ability of Oct4A KD cells
to adhere to fibronectin and collagen I. In the pancreatic
cancer cell line model, diminution of Oct4 was associ-
ated with a decrease in MMP9 expression [48]. In our
study, no such relationship in Oct4A KD cells was
observed. Interestingly however, the Oct4B isoform has
been identified to regulate both MMP2 and MMP9
a b
c
Fig. 8 Immunohistochemical analysis of Glut-1 and CK7 expression in Oct4A knockdown xenografts. a Representative immunohistochemistry staining
images of debulked mouse xenografts for the expression of Glut-1 and CK7. Images are set at 200x magnification and scale bar represents 50 μM.
b-c Quantification of Glut-1 and CK7 staining was determined by using Image J software recognizing DAB intensity. Variations in staining were
determined by subtracting the negative control DAB reading from the DAB reading of the protein of interest for each xenograft. Data is
presented as the mean ± SEM of staining intensity (n = 4/group). Significant variations between Oct4A KD groups and vector control was determined
by Student’s t-test *P < 0.05
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expression in cervical cancer, suggesting the lack of
MMP9 suppression may be due to the fact that Oct4B
expression was not specifically suppressed in the current
study [49].
We also demonstrate that the suppression of Oct4A in
HEY cells resulted in a significant reduction in the
tumor growth, weight and size in Balb/c nude mouse
model. In addition, tumor xenografts derived from
Oct4A KD cells displayed relatively lower abundance of
markers associated with ovarian cancer (CK7), cancer
metabolism (Glut-1) and angiogenesis (CD31 and
CD34). This indicates that the suppression of Oct4A not
only reduced the tumor initiating ability of cells in vivo
but also resulted in a reduction in angiogenic potential
which consequently may have resulted in slowed or ab-
rogated tumor growth. These results are consistent with
the positive correlation between the expression of Oct4
and vasculogenic mimicry formation and poor prognosis
in breast cancer patients [50]. In addition, Oct4 has been
shown to promote glioblastoma progression through
vascular endothelial growth factor production [51].
Importantly, integrins are well documented to play
significant roles in mediating tumor vascularity and
angiogenesis [52]. Specifically, integrin α5β1 has been
identified to play a role in tumor angiogenesis in in vivo
mouse models [53, 54]. Collectively, this tie in with the
reduced expression of β1 and α5 subunits demonstrated
in Oct4A KD cells and overall reduced tumorigenic and
angiogenic profiles in this study.
Conclusions
In summary, while Oct4 has previously been shown to
regulate several processes involved in solid tumor metas-
tasis, the role of the Oct4A isoform in ovarian cancer
progression is still emerging. The results of this study
demonstrate a crucial role for the pluripotent stem cell
specific Oct4A isoform in regulating key events required
for ovarian cancer progression, survival and metastasis.
Importantly, these results were associated with altered
expression of α2, α5 and β1 integrin sub-units. This
study has therefore revealed a complex novel relation-
ship between Oct4A and cell surface membrane recep-
tors which may potentially drive the events involved in
ECM remodeling which are crucial for ovarian cancer
metastasis in the peritoneal microenvironment. From
these results, it could be hypothesized that following
exfoliation into the peritoneal cavity, Oct4A expressing
ovarian tumor cells are capable of regulating the
expression of a specific sub-set of cell surface integrin
receptors. This in turn would assist in the formation
of non-adherent spheres within the ascites fluid of
advanced stage patients thus driving long-term
a b
c
Fig. 9 Immunohistochemical analysis of CD31 and CD34 expression in Oct4A knockdown xenografts. a Representative images of immunohistochemistry
staining of debulked mouse xenograft tumors for the expression of CD31 and CD34. Images are set at 200x magnification and scale bar represents
50 μM. b-c Quantification of CD31 and CD34 staining was determined as described in Figure 9. Significant variations between Oct4A KD groups and
vector control was determined by One-Way ANOVA using Dunnett’s Multiple Comparison post-test **P< 0.01 and *P< 0.05
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tumorigenicity. Moreover, through its regulation of in-
tegrin expression, Oct4A would be able to drive cellu-
lar adhesion, invasion and tumor survival thus
promoting ongoing metastasis (Fig. 10). Overall, the
results of this study collectively suggest targeting
Oct4A through novel therapeutics may help overcome
ovarian cancer peritoneal metastasis.
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